Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 30, 2013. The report serves as a regulatory announcement regarding the submission of a New Drug Application (NDA) in the United States for umeclidinium bromide (UMEC), an investigational once-daily medicine for chronic obstructive pulmonary disease (COPD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on regulatory developments rather than financial performance.
Material Changes
The primary material event is the submission of a regulatory application to the US Food and Drug Administration (FDA) for UMEC monotherapy (62.5mcg pre-dispensed dose). This follows a similar submission in Europe on April 26, 2013. The filing notes that regulatory filings for UMEC monotherapy are planned in other countries during 2013.
Outlook, Risks, and Management Commentary
- Development Pipeline: UMEC is part of a broader respiratory portfolio including UMEC/vilanterol (ANORO), fluticasone furoate/vilanterol (RELVAR/BREO), and other investigational medicines. None of these investigational medicines are currently approved anywhere in the world.
- Forward-Looking Statements: GSK cautions that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's 2012 Annual Report on Form 20-F.
- Regulatory Status: The use of proposed brand names (ANORO, RELVAR, BREO, ELLIPTA) is not yet approved by any regulatory authorities.
Key Facts for Investor Verification
- Confirmation of the FDA acceptance of the NDA for UMEC monotherapy.
- Timeline for regulatory decisions in the US and other planned international filings.
- Progress of the broader respiratory development portfolio, specifically the combination therapies (ANORO, RELVAR/BREO).
- Any updates on the approval status of the ELLIPTA inhaler delivery system.